AMD Likely To Support Server Market Share Gains Versus Intel, Analyst Says

KeyBanc analyst John Vinh reiterated an Overweight rating on Advanced Micro Devices, Inc (NASDAQ:AMD) with an $85 price target. AMD hosted a…
  • KeyBanc analyst John Vinh reiterated an Overweight rating on Advanced Micro Devices, Inc (NASDAQ:AMD) with an $85 price target.
  • AMD hosted a launch event for its fourth-generation EPYC server CPU Genoa, which increased his confidence that the Company will continue to sustain its market share gains in servers, particularly in the cloud vs. Intel Corp (NASDAQ:INTC). 
  • More specifically, AMD, citing benchmark tests vs. INTC’s Ice Lake, indicated the performance of Genoa is 3x more remarkable, 55% faster on a per-core basis, and stated that power efficiency is 48% greater. 
  • Additionally, AMD featured several critical customers, including Microsoft Corp (NASDAQ:MSFT) Azure, GCP, Oracle Corp (NYSE: ORCL), HP Inc (NYSE: HPQ), Dell Technologies Inc (NYSE:DELL), and Lenovo Group Ltd (OTC:LNVGF) (OTC:LNVGY), all providing endorsements for AMD and its latest-generation processors. 
  • Notably, Azure announced it is now in public preview mode on two instance types running Azure. 
  • With INTC’s Sapphire Rapids delay until mid-next year, he saw sustained market gains for AMD in servers through 2023. 
  • Price Action: AMD shares traded higher by 5.27% at $72.08 on the last check Friday.
Total
0
Shares
Related Posts
Read More

Specialty Vehicles Manufacturer REV Group Shares Are Surging Today: What’s Going On?

REV Group Inc (NYSE: REVG) surges over 7% as it unveils strategic initiatives. The sale of Collins Bus Corporation for $303.0 million and the exit from transit bus manufacturing mark significant changes. A special dividend of $3.00 per share, payable on February 16, 2024, reflects the company's commitment towards shareholders.

REVG

Read More

US Intelligence Claims Chinese Pharma Giant Illegally Shared Secrets With Beijing

U.S. intelligence officials have informed senators that WuXi AppTec, a Chinese pharmaceutical company, allegedly transferred U.S. intellectual property to Beijing without authorization. This news comes amid concerns that certain Chinese biotech firms are providing technology or research and development for use by the Chinese military.

WXIBF